Speech dysfluency exacerbated by levodopa in Parkinson's disease.
Identifieur interne : 000523 ( Ncbi/Curation ); précédent : 000522; suivant : 000524Speech dysfluency exacerbated by levodopa in Parkinson's disease.
Auteurs : E D Louis [États-Unis] ; L. Winfield ; S. Fahn ; B. FordSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2001.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antipsychotic Agents.
- chemically induced : Speech Disorders, Stuttering.
- drug therapy : Parkinson Disease.
- Adult, Aged, Drug Therapy, Combination, Humans, Male, Videotape Recording.
Abstract
The role of dopamine in the modulation of speech fluency is complex. In this report we describe two patients with Parkinson's disease whose speech dysfluency was exacerbated by the administration of levodopa. In doing so, we extend the observation that dopaminergic mechanisms may be involved in the regulation of speech fluency. It is important for clinicians to recognize that, in some instances, dopaminergic replacement therapy may exacerbate an underlying dysfluency syndrome in PD.
PubMed: 11391759
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003D28
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :003D28
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003C40
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000523
Links to Exploration step
pubmed:11391759Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Speech dysfluency exacerbated by levodopa in Parkinson's disease.</title><author><name sortKey="Louis, E D" sort="Louis, E D" uniqKey="Louis E" first="E D" last="Louis">E D Louis</name><affiliation wicri:level="4"><nlm:affiliation>The Gertrude H. Sergievsky Center, Columbia University, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Gertrude H. Sergievsky Center, Columbia University, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region><settlement type="city">New York</settlement></placeName><orgName type="university">Université Columbia</orgName></affiliation></author><author><name sortKey="Winfield, L" sort="Winfield, L" uniqKey="Winfield L" first="L" last="Winfield">L. Winfield</name></author><author><name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S" last="Fahn">S. Fahn</name></author><author><name sortKey="Ford, B" sort="Ford, B" uniqKey="Ford B" first="B" last="Ford">B. Ford</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2001">2001</date><idno type="RBID">pubmed:11391759</idno><idno type="pmid">11391759</idno><idno type="wicri:Area/PubMed/Corpus">003D28</idno><idno type="wicri:Area/PubMed/Curation">003D28</idno><idno type="wicri:Area/PubMed/Checkpoint">003C40</idno><idno type="wicri:Area/Ncbi/Merge">000523</idno><idno type="wicri:Area/Ncbi/Curation">000523</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Speech dysfluency exacerbated by levodopa in Parkinson's disease.</title><author><name sortKey="Louis, E D" sort="Louis, E D" uniqKey="Louis E" first="E D" last="Louis">E D Louis</name><affiliation wicri:level="4"><nlm:affiliation>The Gertrude H. Sergievsky Center, Columbia University, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Gertrude H. Sergievsky Center, Columbia University, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region><settlement type="city">New York</settlement></placeName><orgName type="university">Université Columbia</orgName></affiliation></author><author><name sortKey="Winfield, L" sort="Winfield, L" uniqKey="Winfield L" first="L" last="Winfield">L. Winfield</name></author><author><name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S" last="Fahn">S. Fahn</name></author><author><name sortKey="Ford, B" sort="Ford, B" uniqKey="Ford B" first="B" last="Ford">B. Ford</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2001" type="published">2001</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (adverse effects)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Male</term><term>Parkinson Disease (drug therapy)</term><term>Speech Disorders (chemically induced)</term><term>Stuttering (chemically induced)</term><term>Videotape Recording</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Speech Disorders</term><term>Stuttering</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Male</term><term>Videotape Recording</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The role of dopamine in the modulation of speech fluency is complex. In this report we describe two patients with Parkinson's disease whose speech dysfluency was exacerbated by the administration of levodopa. In doing so, we extend the observation that dopaminergic mechanisms may be involved in the regulation of speech fluency. It is important for clinicians to recognize that, in some instances, dopaminergic replacement therapy may exacerbate an underlying dysfluency syndrome in PD.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000523 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000523 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:11391759
|texte= Speech dysfluency exacerbated by levodopa in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:11391759" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |